CARDIOVASCULAR OUTCOMES FOLLOWING BORTEZOMIB REINITIATION AFTER CONGESTIVE HEART FAILURE DIAGNOSIS IN MULTIPLE MYELOMA

Valentina Jaramillo Restrepo,Vishal Shah,Tania Jain,Jeremy T. Larsen,Hemalatha Narayanasamy,Reza Arsanjani,B.W. Hardaway,Farouk Mookadam,Carolyn M. Larsen

CARDIOVASCULAR OUTCOMES FOLLOWING BORTEZOMIB REINITIATION AFTER CONGESTIVE HEART FAILURE DIAGNOSIS IN MULTIPLE MYELOMA

2020

Valentina Jaramillo Restrepo
Vishal Shah
Tania Jain
Jeremy T. Larsen
Hemalatha Narayanasamy
Reza Arsanjani
B.W. Hardaway
Farouk Mookadam
Carolyn M. Larsen

The incidence of congestive heart failure (CHF) in multiple myeloma (MM) patients treated with proteasome inhibitor therapy is reported at 2% - 5%. However, the data are limited regarding safety of resuming proteasome inhibitor therapy after a diagnosis of CHF. A retrospective chart review was

Keywords:

Diabetes mellitus
Cardiology
Bortezomib
Medicine
Internal medicine
Heart failure
Multiple myeloma
Proteasome inhibitor
chart review
cardiovascular outcomes

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations